Cargando…

Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia

SIMPLE SUMMARY: Acute myeloid leukemia (AML) is a dangerous cancer of the blood. In recent years, a series of drugs was approved to specifically target misdirected processes in the cancerous cells. These so-called “small molecules” substantially improved therapeutic outcomes, but eventually leukemia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lang, Tonio Johannes Lukas, Damm, Frederik, Bullinger, Lars, Frick, Mareike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526197/ https://www.ncbi.nlm.nih.gov/pubmed/37760544 http://dx.doi.org/10.3390/cancers15184573

Ejemplares similares

Clonal hematopoiesis of indeterminate potential-related epigenetic age acceleration correlates with clonal hematopoiesis of indeterminate potential clone size in patients with high morbidity
por: Feldkamp, Jasper David, et al.
Publicado: (2022)

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
por: Halik, Adriane, et al.
Publicado: (2022)

New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise
por: Bohl, Stephan R., et al.
Publicado: (2019)

Mechanisms of drug resistance in acute myeloid leukemia
por: Zhang, Jing, et al.
Publicado: (2019)

Small molecule activation of NOTCH signaling inhibits acute myeloid leukemia
por: Ye, Qi, et al.
Publicado: (2016)

Adhesion molecules in acute myeloid leukemia()
por: Paietta, Elisabeth
Publicado: (1996)

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
por: Eguchi, Motoki, et al.
Publicado: (2020)

Small‐molecule Hedgehog inhibitor attenuates the leukemia‐initiation potential of acute myeloid leukemia cells
por: Fukushima, Nobuaki, et al.
Publicado: (2016)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
por: Minuesa, Gerard, et al.
Publicado: (2019)

Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia
por: Gurnari, Carmelo, et al.
Publicado: (2020)

Resistance to targeted therapies in acute myeloid leukemia
por: Mecklenbrauck, Rabea, et al.
Publicado: (2022)

Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9
por: Christen, Friederike, et al.
Publicado: (2021)

MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia
por: Frech, Miriam, et al.
Publicado: (2018)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia
por: Zhuang, Xiaomei, et al.
Publicado: (2022)

Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells
por: Niu, Jialan, et al.
Publicado: (2022)

Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD(+) Acute Myeloid Leukemia
por: Bregante, Javier, et al.
Publicado: (2021)

Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance
por: Lachowiez, Curtis A., et al.
Publicado: (2023)

Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia
por: Takam Kamga, Paul, et al.
Publicado: (2019)

Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients
por: Lauber, Chris, et al.
Publicado: (2020)

Acute Myeloid Leukemia: Is It T Time?
por: Khoud, Meriem Ben, et al.
Publicado: (2021)

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
por: McNeer, Nicole A., et al.
Publicado: (2019)

Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia
por: Takam Kamga, Paul, et al.
Publicado: (2020)

Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia
por: Sweta, Jajoriya, et al.
Publicado: (2019)

Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
por: Liu, Yiman, et al.
Publicado: (2022)

Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression
por: Li, Jiahui, et al.
Publicado: (2023)

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
por: Scholl, Sebastian, et al.
Publicado: (2020)

Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?
por: Ciciarello, Marilena, et al.
Publicado: (2021)

Leukemic stem cells and therapy resistance in acute myeloid leukemia
por: Stelmach, Patrick, et al.
Publicado: (2023)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs
por: Zebisch, Armin, et al.
Publicado: (2016)

B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia
por: Wilde, Lindsay, et al.
Publicado: (2020)

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia
por: Sharma, Priyanka, et al.
Publicado: (2023)

Classification of acute myeloid leukemia
por: Hwang, Sang Mee
Publicado: (2020)

Tipifarnib in the treatment of acute myeloid leukemia
por: Thomas, Xavier, et al.
Publicado: (2007)

Differentiation Therapy of Acute Myeloid Leukemia
por: Gocek, Elzbieta, et al.
Publicado: (2011)

Comparative proteomics in acute myeloid leukemia
por: Luczak, Magdalena, et al.
Publicado: (2012)

Precision therapy for acute myeloid leukemia
por: Yang, Xue, et al.
Publicado: (2018)

Novel Agents for Acute Myeloid Leukemia
por: Luppi, Mario, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tlt35pslgf2b8e5paub2a5v6ud